11 research outputs found
ATV and RAL pharmacokinetic parameters in different dosing strategies.
<p>ATV and RAL pharmacokinetic parameters in different dosing strategies.</p
Changes from baseline in main laboratory parameters.
<p>ATV/r or ATV: Boosted or Unboosted Atazanavir; RAL: Raletgravir; ALT: Alanine aminotransferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.</p
Cumulative probability of treatment success according with ritonavir association.
<p>Survival curves by time to loss of virological response analysis, according to virological failure (A) and treatment failure (B). ATV/r or ATV: Boosted or Unboosted Atazanavir, RAL: Raltegravir.</p
Significant predictors associated with virological failure and therapeutic failure.
<p>Significant predictors associated with virological failure and therapeutic failure.</p
Reasons for stopping dual therapy before week 96 (n = 132).
<p>Reasons for stopping dual therapy before week 96 (n = 132).</p
Study’s flowchart.
<p>* Cohort of HIV-infected patients consulting in infectious department during 1 year. ** Dedicated questionnaire + Hand-Held spirometer.</p
Baseline characteristics of study cohort: comparison included/excluded.
<p>Baseline characteristics of study cohort: comparison included/excluded.</p
Comparison COPD-patients and non-COPD patients.
<p>Comparison COPD-patients and non-COPD patients.</p
Standardized difference between statin users and non users.
<p>Abbreviations: BMI = body mass index, HCV = hepatitis C virus, HBs = hepatitis B, AIDS = acquired immune deficiency syndrome.</p